ERBB2 and gastric cancer: Two recent phase II studies showed impressive results of agents targeting claudin-18 isoform 2 (zolbetuximab) and fibroblast growth factor receptor-2 isoform IIIb (bemarituzumab)35 in combination with first-line chemotherapy for patients with HER2-negative gastric cancer.